Literature DB >> 9192993

Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder.

L Moltó1, J Carballido, L Manzano, E Reyes, C Olivier, M Alvarez-Mon.   

Abstract

The immunomodulatory effect of prophylactic intravesical instillations of interferon alpha 2b (IFN-alpha-2b) on interferon gamma (IFN-gamma) and interleukin 4 (IL-4) production by peripheral blood mononuclear cells (PBMCs) from patients with superficial transitional cell carcinoma (STCC) of the bladder has been analysed. There were no significant differences in the production of IFN-gamma and IL-4 by PBMCs from untreated patients and healthy control subjects after 24 h of phytohaemagglutinin (PHA) stimulation. However, between 3 and 6 months after finishing the prophylactic intracavitary treatment with IFN-alpha-2b, PHA-stimulated PBMCs from patients with STCC of the bladder showed a significantly enhanced production of IFN-gamma and a significantly decreased production of IL-4. Both IFN-gamma and IL-4 returned to pretreatment levels 1 year after ending the treatment. In conclusion, prophylactic intravesical instillations of IFN-alpha-2b in patients with STCC of the bladder have an immunoregulatory effect on the production of IFN-gamma and IL-4 by PBMCs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192993      PMCID: PMC2223628          DOI: 10.1038/bjc.1997.315

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression.

Authors:  R Kaempfer; L Gerez; H Farbstein; L Madar; O Hirschman; R Nussinovich; A Shapiro
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes.

Authors:  S Ikemoto; T Kishimoto; S Wada; S Nishio; M Maekawa
Journal:  Br J Urol       Date:  1990-04

3.  Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.

Authors:  C M Higuchi; J A Thompson; C G Lindgren; S Gillis; M B Widmer; D E Kern; A Fefer
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

4.  A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder.

Authors:  R W Glashan
Journal:  J Urol       Date:  1990-09       Impact factor: 7.450

5.  IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.

Authors:  H Spits; H Yssel; X Paliard; R Kastelein; C Figdor; J E de Vries
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

6.  Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets.

Authors:  T Kasahara; J J Hooks; S F Dougherty; J J Oppenheim
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

7.  Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.

Authors:  C D Jurincic; U Engelmann; J Gasch; K F Klippel
Journal:  J Urol       Date:  1988-04       Impact factor: 7.450

Review 8.  Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy.

Authors:  F M Torti; B L Lum
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

9.  Induction of interferon-gamma production by human natural killer cells stimulated by hydrogen peroxide.

Authors:  T Munakata; U Semba; Y Shibuya; K Kuwano; M Akagi; S Arai
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Alpha interferon as an immunomodulator in the treatment of patients with tumors.

Authors:  M Alvarez-Mon; O J Salmerón; L Manzano; M Rodríguez-Zapata; E Reyes; L M Vaquer; J Carballido
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

2.  Relationship between response to interferon-alpha and function of peripheral blood mononuclear cells in chronic hepatitis C patients.

Authors:  Fatima Esquivel; Agustín Albillos; Flavio Carrión; Alfredo Prieto; Eduardo Reyes; Belén Martínez-Martin; José Luis Calleja; Guillermo Cacho; Melchor Alvarez-Mon
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

3.  The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.

Authors:  E Reyes; J Carballido; L Manzano; L Moltó; C Olivier; M Alvarez-Mon
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

4.  Integrated Analysis of Key Pathways and Drug Targets Associated With Vogt-Koyanagi-Harada Disease.

Authors:  Zhijun Chen; Zhenyu Zhong; Wanyun Zhang; Guannan Su; Peizeng Yang
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.